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Objective. There are few clinical predictors of the progression of systemic sclerosis (SSc)-related interstitial lung disease (ILD). The purpose of this study was to examine the predictive significance of key cytokines for long-term progression of ILD and survival in 2 independent cohorts of patients with early SSc.
Methods. Plasma levels of 11 Th1/Th2 cytokines (interleukin-1b [IL-1b], IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, tumor necrosis factor, CCL2, interferon-inducible T cell a chemoattractant, and interferon-g-inducible 10-kd protein) were measured in 266 patients with early SSc in the Genetics versus Environment in Scleroderma Outcome Study (GENISOS) discovery cohort. Levels of CCL2, IL-10, and IL-6 were measured in 171 patients with early SSc in the Canadian Scleroderma Research Group (CSRG) replication cohort. The primary outcome measure was a decline in the forced vital capacity percent predicted (FVC%) value over time. A joint analysis of longitudinal FVC% values and survival was performed.
Results. After adjustment for age, sex, and ethnicity, CCL2 and IL-10 were found to be significant predictors of ILD progression in the discovery cohort. Higher CCL2 levels predicted a faster decline in FVC% values (b 5 20.57, P 5 0.032), while higher IL-10 levels predicted a slower decline (b 5 0.26, P 5 0.01). A higher CCL2 value was also predictive of poorer survival (hazard ratio 1.76, P 5 0.030). In the CSRG replication cohort, higher CCL2 levels predicted a faster decline in FVC% values (b 5 20.58, P 5 0.038), but neither IL-10 nor IL-6 had predictive significance. A higher CCL2 level also predicted poorer survival (hazard ratio 3.89, P 5 0.037).
Conclusion. Higher CCL2 levels in the circulation were predictive of ILD progression and poorer survival in patients with early SSc, findings that support the notion that CCL2 has a role as a biomarker and potential therapeutic target.
Systemic sclerosis (SSc) is an autoimmune, fibrotic disease with high rates of disease-related morbidity and mortality (1) . Pulmonary involvement, including interstitial lung disease (ILD), has become the leading cause of SScrelated death (2, 3) . The course of ILD is highly variable, and predictive biomarkers could lead to more effective and individualized monitoring and treatment strategies. Previously, we investigated the predictive significance of a comprehensive list of demographic and autoantibody variables, including disease types, for long-term ILD progression. None of the selected baseline variables predicted a long-term decline in the forced vital capacity percent predicted (FVC%) value (4). In a follow-up study, the C-reactive protein (CRP) level at baseline predicted longterm ILD progression in SSc (5) . Another recent study indicated that the serum interleukin-6 (IL-6) level was predictive of ILD progression in patients with SSc (6) .
SSc patients have a distinct cytokine profile (7). However, the predictive significance of these cytokines for long-term progression of ILD has not been established in early SSc cohorts. The objective of the present study was to investigate the predictive significance of circulating levels of Th1/Th2 cytokines/chemokines at baseline for the progression of ILD, using highly sensitive multiplex assays in 2 large, independent cohorts of patients with early SSc.
PATIENTS AND METHODS
Study population. The Genetics versus Environment in Scleroderma Outcome Study (GENISOS) is a collaborative effort of the University of Texas Health Science Center (UTHSC) at Houston, the UTHSC at San Antonio, and the University of Texas Medical Branch at Galveston. At the time of cytokine determination, 266 SSc patients with early SSc had been enrolled. All patients fulfilled the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for SSc (8) and had a disease duration of ,5 years at the time of enrollment (time from the first non-Raynaud's phenomenon symptom to enrollment). Diffuse skin involvement was present in 156 patients (59%), and the mean disease duration (determined from the time of the first non-Raynaud's phenomenon symptom) at enrollment was 2.5 years (data available upon request from the corresponding author). Requirements for enrollment in GENISOS were age $18 years and diagnosis of SSc made by the local GENISOS rheumatologist investigator. At the time of the death search query, 86 patients (32.3%) had died.
For the replication cohort, 171 eligible patients were identified in the Canadian Scleroderma Research Group (CSRG) registry. These patients had a disease duration of ,5 years, available serum samples, and at least 2 pulmonary function test results. CSRG registry patients were required to have been diagnosed as having SSc by a CSRG rheumatologist, be $18 years old, and be fluent in English or French. More than 98% of the CSRG patients met the 2013 ACR/EULAR classification criteria for SSc (9) . Diffuse skin involvement was present in 66 patients (39%), and the mean disease duration in these patients was 2.2 years (further information available upon request from the corresponding author). Among the CSRG cohort, 19 patients (11%) had died at the time of the death search query.
Cytokine/chemokine determinations. Plasma samples obtained at the baseline visit from 266 SSc patients in the GENISOS cohort as well as from 97 age-, sex-, and ethnicitymatched healthy controls were examined for cytokine/chemokine levels. The blood samples were collected into tubes containing EDTA. Cells were removed by centrifugation for 10 minutes at 2,600 revolutions per minute, and the plasma was stored at 2808C until analyzed. The plasma had not undergone more than 2 freeze-thaw cycles before the chemokine levels were determined. In the first step, 11 key Th1/Th2 cytokines and chemokines were measured in the GENISOS cohort: IL-1b, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, tumor necrosis factor (TNF), CCL2 (also known as monocyte chemoattractant protein 1 [MCP-1]), interferon-inducible T cell a chemoattractant (I-TAC; also known as CXCL11), and interferon-g-inducible 10-kd protein (IP-10). In the replication step, IL-6, IL-10, and CCL2 were measured according to the same methods in serum obtained at baseline from 171 patients in the CSRG cohort.
All cytokines were quantified with a highly sensitive multiplex sandwich immunoassay (Meso Scale Discovery) using an electrochemiluminescence system and following the protocol recommended by the manufacturer. Each sample was run in duplicate. All measurements had a coefficient of variation of ,0.2.
Severity of SSc-related ILD. Pulmonary function tests were performed at the initial visit and annually thereafter. FVC% as a continuous variable was used as a surrogate for the severity of SSc-related ILD, as this has been demonstrated to be a valid outcome measure for ILD severity in randomized controlled studies of patients with SSc (10) . Longitudinal analysis of FVC% values was based on 1,016 individual FVC% measurements in the GENISOS cohort and 968 in the CSRG cohort. The mean follow-up time in the GENISOS cohort was 4.36 years (maximum 13.1 years), and in the CSRG cohort, it was 5.72 years (maximum 9.71 years). The rate of change in longitudinally obtained FVC% values served as a surrogate measure of ILD progression.
Determination of vital status. All deaths were recorded prospectively in the database. To ensure complete capture of vital status in the GENISOS cohort, a National Death Index query was also performed.
Statistical analysis. All of the cytokine values were log-transformed. Differences in cytokine levels between patients and controls were investigated by t-test. Pearson's correlations were calculated for cytokine levels versus baseline FVC% values. Linear regression analysis was also used to examine the univariable and multivariable associations between the cytokine values and the baseline FVC% values.
A joint analysis of longitudinal data (sequentially obtained FVC%) and survival data was also conducted in order to investigate the predictive significance of the baseline cytokine levels (as a continuous variable) for the long-term change in the FVC%. This analysis allows inclusion of all FVC% measurements and adjusts for baseline differences in the FVC% (random intercept). Furthermore, it accounts for the association between FVC% and survival, and reduces the bias resulting from the fact that patients with more rapid decline in the FVC% have a higher mortality rate (4) . The longitudinal component consisted of a linear model with random effects. The ultimate goal of this analysis 1872 WU ET AL was to examine whether baseline cytokine levels had predictive significance for a faster (or slower) decline in the FVC% over time. This was investigated by the interaction term of the cytokine level and follow-up time (11) . We focused on the interaction term between the cytokine and follow-up time rather than the main effect of cytokine as the main predictor variable because a time component has to be included to determine the rate of change in the outcome variable (i.e., the FVC%). The main effect would provide information on the association with serially obtained FVC% values but would not identify cytokines that are associated with a faster (or slower) rate of decline in the FVC%. The survival component fitted a parametric Weibull model with the cytokines as predictors. The starting point of the survival analysis was time of enrollment. The overall Wald chi-square test was highly significant (P , 0.001) for the final models, indicating a significant association between the predictors in the models and the FVC%. We also evaluated model fit with various marginal and subject-specific residual diagnostic plots. No deviations from the model assumptions were evident in any of the plots (12) .
RESULTS
Findings in the discovery cohort. Comparison of cytokine/chemokine levels in SSc patients versus healthy controls. First, we investigated 11 key Th1/Th2 cytokines/chemokines, namely, IL-1b, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, TNF, CCL2, I-TAC, and IP-10, in plasma samples from 266 SSc patients and 97 age-, sex-, and ethnicity-matched unaffected controls. SSc patients had significantly higher plasma levels of IL-6, IL-8, IL-10, TNF, CCL2, I-TAC, and IP-10 compared to unaffected controls ( Figure 1 and data available upon request from Figure 1 . Comparison of plasma cytokine/chemokine levels in Genetics versus Environment in Scleroderma Outcome Study (GENISOS) patients versus controls. Plasma samples from 266 systemic sclerosis (SSc) patients and 97 age-, sex-, and ethnicity-matched unaffected controls were collected, and the levels of interleukin-1b (IL-1b), IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, tumor necrosis factor (TNF), CCL2, interferon-inducible T cell a chemoattractant (I-TAC), and interferon-g-inducible 10-kd protein (IP-10) were measured by multiplex platform assay. Data are shown as box plots. The depth of the boxes represents the interquartile range (IQR). Lines inside the boxes represent the median. Lower lines outside the boxes represent the smallest observed value that is greater than or equal to the 25th percentile plus 1.5 times the IQR. Upper lines outside the boxes represent the largest observed value that is less than or equal to the 75th percentile plus 1.5 times the IQR. Circles indicate outliers. the corresponding author). Limiting the analysis to patients not treated with immunosuppressive agents at the baseline visit did not change the observed significant associations (data available upon request from the corresponding author).
Correlation of baseline cytokine levels with baseline FVC%. Next, we investigated the correlation of cytokine levels with the concomitantly obtained FVC% values at the cross-sectional level. After adjustment for age, sex, and African American race, higher IL-1b, IL-6, IL-8, IL-10, IL-13, CCL2, I-TAC, and IP-10 levels were associated with more severe restrictive lung disease at the baseline visit (i.e., significant negative correlation with the concomitantly obtained FVC% value), although the observed associations were relatively weak (r . 20.3) ( Table 1) .
Predictive significance of baseline cytokine levels for ILD progression. In the longitudinal analysis after adjustment for age, sex, and African American race, higher CCL2 levels predicted a faster decline in the FVC% (b 5 20.57 [95% CI 21.11, 20 .04], P 5 0.032), while higher IL-10 levels predicted a slower decline in the FVC% (b 5 0.26 [95% CI 0.06, 0.46], P 5 0.01) and had a protective effect (Table 2) . Similarly, higher IL-5 and IL-12 levels (P 5 0.015 and P 5 0.018, respectively) were also predictive of a slower decline in the FVC% (Table 2) . However, IL-10, IL-12, and IL-5 were highly correlated with each other (r . 0.8) (data available upon request from the corresponding author). Due to problems arising from multicollinearity, these 3 cytokines could not be investigated in the same multivariable model. From among these 3 cytokines, IL-10 was pursued in the follow-up analyses because plasma IL-10 showed significant differential levels in the comparison of patients versus controls and had the strongest correlations with the FVC% in the crosssectional analysis ( Figure 1 and Table 1 ).
The predictive significance of CCL2 and IL-10 remained significant in a multivariable analysis that included both the CCL2 and IL-10 cytokines with the disease type (diffuse cutaneous versus limited cutaneous SSc), immunosuppressive treatment status at the baseline visit, anti-topoisomerase I (anti-topo I) antibody, and Table 2 ). Of note, IL-6, similar to CCL2 and IL-10, was associated with lower serially obtained FVC values (i.e., main effect in Table 2 ), which paralleled the findings at the cross-sectional level (Table 1) . In survival analyses, higher CCL2 levels were also predictive of shorter survival (hazard ratio [HR] 1.76 [95% CI 1.06, 2.93], P 5 0.030), whereas IL-10 was not predictive of survival (HR 0.99 [95% CI 0.83, 1.18], P 5 0.896) after adjustment for age, sex, and African American race. Higher CCL2 levels also showed a trend toward predicting poorer survival (P 5 0.088), whereas IL-10 did not predict survival (P 5 0.763) in the extended model.
In a secondary analysis, we investigated whether CCL2 or IL-10 predicted the progression rate for the mod- Findings in the replication cohort. Next, we analyzed the association of CCL2 and IL-10 with the FVC% using serum samples from the CSRG replication cohort. We also investigated IL-6 levels in this cohort because IL-6 was predictive of FVC% progression in a previous study (6) and has been recently proposed as a treatment target in SSc (13) . Consistent with results in the discovery cohort, both CCL2 and IL-10 showed a significant negative correlation with the concomitantly obtained FVC% (r 5 20.22, P 5 0.004 and r 5 20.18, P 5 0.024, respectively). IL-6 also showed a significant negative correlation (r 5 20.19, P 5 0.016). The strength of correlations was also in the similar range.
In the simple longitudinal model, the predictive significance of the 3 cytokines CCL2, IL-10, and IL-6 was investigated after adjustment for age and sex (data available upon request from the corresponding author). African American race was not included in the model because only 3 patients in the CSRG cohort were African American. Higher CCL2 levels were a significant predictor of faster ILD progression (b 5 20.58 [95% CI 21.14, 20.03], P 5 0.038) (data available upon request from the corresponding author), while IL-6 and IL-10 levels were not predictive of a differential rate in FVC% progression (P 5 0.068 and P 5 0.859, respectively). Of note, all 3 cytokines were associated with lower serially obtained FVC% levels, which again paralleled the results of the crosssectional analysis results.
In the extended model, CCL2 showed predictive significance for a faster decline in the FVC% (b 5 20.55 [95% CI 21.08, 20.01], P 5 0.046) after adjustment for disease subtype, immunosuppression status, presence of topo I antibodies, natural log-transformed CRP values, age, and sex (Table 4 ). Higher CCL2 levels were also predictive of poorer survival (HR 3.89 [95% CI 0.23, 7.55], P 5 0.037) in the CSRG cohort.
DISCUSSION
Using a highly sensitive multiplex assay, we showed that SSc patients, regardless of treatment, had higher plasma levels of IL-6, IL-8, IL-10, TNF, CCL2, I-TAC, CCL2 PREDICTS SSc-RELATED ILD PROGRESSIONand IP-10 compared to control subjects. Subsequently, we demonstrated for the first time that CCL2 levels in the circulation were predictive of faster, long-term decline in FVC% in 2 independent, well-characterized early SSc cohorts. Furthermore, CCL2 was predictive of poorer survival. IL-10 levels were predictive of a slower decline in the FVC% in the GENISOS cohort, but this finding was not replicated in the CSRG cohort.
In a large-scale global gene expression study of the skin, we previously found that CCL2 messenger RNA (mRNA) and plasma levels correlated with concomitantly obtained FVC%. Furthermore, immunofluorescence staining revealed that CCL2 was overexpressed in fibroblasts from the affected skin and lung tissue obtained from SSc patients as compared to controls (14) . In a previous study, CCL2 was found to be highly up-regulated in bronchoalveolar lavage fluid from patients with SSc-related ILD compared to healthy controls or with ILD-negative SSc patients. Furthermore, patients with a high score ($29) on high-resolution computed tomography (HRCT) had higher CCL2 levels when compared to patients with fewer fibrotic changes (15) .
CCL2 also stimulated, in a dose-dependent manner, the expression of procollagen a1 mRNA on rat lung fibroblasts (16) . In another study, CCL2 (MCP-1) was highly expressed in dermal fibroblasts from SSc patients but not from unaffected controls (17) . Furthermore, antibody blocking of CCL2 decreased the chemotactic activity of fibroblasts. Although an increase in the level of type I procollagen over time was noted in that study, there was no significant effect of recombinant CCL2 on procollagen a1(I) mRNA expression in SSc or healthy dermal fibroblasts (17) . CCL2-blocking antibody also significantly inhibited the expression of a-smooth muscle actin in cultured SSc dermal fibroblasts (18) . In a mouse model of bleomycin-induced dermal fibrosis, administration of anti-CCL2 neutralizing antibody reduced the degree of dermal fibrosis. Stimulation with CCL2 up-regulated procollagen a1 mRNA in normal human fibroblasts, as determined by Northern blot hybridization (19) . CCL2 might also contribute to polarization of macrophages to a profibrotic subtype (20) , which has been implicated in the pathogenesis of SSc (21) . These studies indicated that CCL2 might contribute to the fibrotic signaling pathways through its biologic functions. Future studies are needed to elucidate the role of CCL2 in this potentially important profibrotic mechanism in SSc.
Reliable prediction models using molecular data are needed in SSc-related ILD, as its course is highly variable and clinical characteristics alone do not predict the long-term rate of decline in the FVC% (4) . We previously demonstrated that baseline CRP levels predict a long-term decline in the FVC% (5) . Importantly, the predictive significance of CCL2 was independent of baseline CRP levels in the present study, indicating that this cytokine can provide predictive information beyond CRP.
In the present study, a higher IL-10 level predicted a slower decline in the FVC% and had a protective effect in the GENISOS cohort. Several mechanistic studies have indicated that IL-10 might have antifibrotic effects in the lung tissue. IL-10 gene delivery significantly suppressed hydroxyproline and transforming growth factor b production in a mouse model of bleomycin-induced lung fibrosis (22) . Furthermore, IL-10 attenuated chronic lipopolysaccharide-induced airway inflammation and subepithelial fibrosis (23) . Although the antifibrotic effect of IL-10 in the GENISOS cohort is supported by the above animal model studies, this finding was not replicated in the CSRG cohort. Therefore, further studies are needed to investigate the potential role of circulating IL-10 as a protective biomarker for ILD progression.
The cytokine studies in the GENISOS cohort were performed on plasma samples, whereas in the CSRG cohort, serum samples were used. We focused on plasma samples in the GENISOS cohort in order to avoid artificial fluctuations in cytokine levels resulting from coagulation. Plasma samples were not available in the CSRG biorepository; thus, the confirmatory assays were conducted in serum samples. The fact that CCL2 showed predictive significance in both sample types underscores the robustness of this cytokine as a biomarker.
Another cytokine, IL-6, has been investigated in previous studies, and the serum IL-6 level was found to be an independent predictor of a decline in the FVC% and the % predicted diffusing capacity for carbon monoxide in SSc (6) . In the present study, IL-6 did not predict a faster decline in the FVC% in either the GENISOS cohort or the CSRG cohort, although it was associated with lower FVC% levels in both cohorts (i.e., the main effect in the joint analysis).
Other potential candidate proteins for predicting the course of SSc-related ILD are pneumoproteins. These proteins are linked to lung parenchymal injury. Specifically, surfactant protein D, CCL18, and Krebs von den Lungen 6 (KL-6) have been studied as potential biomarkers. In a previous study, surfactant protein D and CCL18 were not predictive of long-term ILD progression in the GENISOS cohort (24) . In a recently published study of 50 patients with untreated early SSc-related ILD, higher levels of KL-6 antibody were predictive of the development of end-stage lung disease (defined as an FVC% of ,50%, need for continuous oxygen supplementation, or death due to ILD) (25) . A threshold of 1,273 units/ml for the serum KL-6 level had a sensitivity of 87.5% and a specificity of 100% for identifying patients who developed end-stage lung disease (25) . Future independent studies are needed to confirm the predictive significance of KL-6 in general and the aforementioned threshold value in particular for SSc-related ILD progression.
There are several strengths of the present study. We conducted the study in 2 independent, wellcharacterized cohorts of patients with early SSc. The mean disease duration in the GENISOS cohort and subgroup of CSRG cases was 2.5 years and 2.2 years, respectively. The focus on early disease avoids problems arising from survival bias. Furthermore, we used analytical models that allow the inclusion of all long-term, prospectively obtained FVC% measurements (1,016 and 968 pulmonary function tests in the GENISOS and CSRG cohorts, respectively) and account for the fact that patients with faster ILD progression have higher mortality rates (nonrandom missing data). Another strength of our study is that we used multiplex platform assays (Mesoscale Discovery) that are more sensitive than conventional enzyme-linked immunosorbent assays or most other multiplex platforms (e.g., Luminex), providing a higher dynamic range and more accurate measurement of low-abundance chemokines/cytokines (26) .
Our study also has some weaknesses. It was conducted in an observational cohort in which treatment regimens are heterogeneous, although we tried to address this limitation by adjusting for baseline treatment with immunosuppressive agents in our multivariable models. However, we cannot exclude residual confounding. Therefore, this study was not well-suited for developing predictive biomarkers for response to specific therapeutic agents. Furthermore, we did not restrict our analysis to patients who already had evidence of ILD on HRCT at the baseline visit because the HRCT information was not available in all patients. However, we used the rate of decline in the FVC% as a surrogate for ILD progression, and patients who do not have clinically significant ILD should not have an accelerated decline in the FVC%. Another limitation is that we examined the overall mortality rather than SScspecific mortality because reliable data on causes of death were not available for our samples.
The present study provides evidence that higher baseline levels of CCL2 in the circulation predict a faster decline in lung function in SSc patients and can be used to identify patients at risk of more rapid progression of ILD. It also provides further support for CCL2 as a treatment target in SSc-related ILD.
